We are live on ! Find out more
IMMU

Immunomedics Inc
IMMU

Delisted

IMMU was delisted on the 22nd of October, 2020.

Back to rankings

207 hedge funds and large institutions have $3.08B invested in Immunomedics Inc in 2018 Q3 according to their latest regulatory filings, with 41 funds opening new positions, 81 increasing their positions, 53 reducing their positions, and 26 closing their positions.

New
Increased
Maintained
Reduced
Closed

58% more first-time investments, than exits

New positions opened: 41 | Existing positions closed: 26

53% more repeat investments, than reductions

Existing positions increased: 81 | Existing positions reduced: 53

8% more funds holding

Funds holding: 192 → 207 (+15)

0% more funds holding in top 10

Funds holding in top 10: 9 → 9 (0)

11% less capital invested

Capital invested by funds: $3.48B → $3.08B (-$400M)

44% less call options, than puts

Call options by funds: $99.7M | Put options by funds: $177M

Holders
207
Holders Change
+15
Holders Change %
+7.81%
% of All Funds
4.73%
Holding in Top 10
9
Holding in Top 10 Change
–
Holding in Top 10 Change %
–
% of All Funds
0.21%
New
41
Increased
81
Reduced
53
Closed
26
Calls
$99.7M
Puts
$177M
Net Calls
-$76.9M
Net Calls Change
-$11.5M

Top Buyers

Rank Fund Capital Flow
1
T. Rowe Price Associates
T. Rowe Price Associates
Maryland
+$90.5M
2
CS
Candriam SCA
Luxembourg
+$24.3M
3
BlackRock
BlackRock
New York
+$23.1M
4
WRF
Waddell & Reed Financial
Kansas
+$17.8M
5
Deutsche Bank
Deutsche Bank
Germany
+$16.8M

Top Sellers

Rank Fund Capital Flow
1
Millennium Management
Millennium Management
New York
-$70.8M
2
Fidelity Investments
Fidelity Investments
Massachusetts
-$69.5M
3
ACP
Acuta Capital Partners
California
-$63.8M
4
O
OrbiMed
New York
-$14.6M
5
Citadel Advisors
Citadel Advisors
Florida
-$12.3M
Name Holding Trade Value Shares
Change 		Change in
Stake
Renaissance Technologies
51
Renaissance Technologies
New York
$10.7M +$10.4M +440,300 +587%
MMH
52
Menora Mivtachim Holdings
Israel
$10.6M – – –
Barclays
53
Barclays
United Kingdom
$9.5M +$2.88M +121,519 +36%
RPAM
54
Rhenman & Partners Asset Management
Sweden
$8.86M -$711K -30,000 -7%
Wells Fargo
55
Wells Fargo
California
$7.83M +$561K +23,676 +7%
GIM
56
Granahan Investment Management
Massachusetts
$7.69M +$310K +13,100 +4%
HI
57
HBK Investments
Texas
$6.76M +$7.68M +324,320 New
AA
58
ALPS Advisors
Colorado
$6.65M +$1.83M +77,451 +32%
TD Asset Management
59
TD Asset Management
Ontario, Canada
$6.47M +$2.27M +95,700 +44%
Group One Trading
60
Group One Trading
Illinois
$6.29M +$1.34M +56,635 +23%
Adage Capital Partners
61
Adage Capital Partners
Massachusetts
$6.04M +$3.32M +140,000 +93%
TCIM
62
TIAA CREF Investment Management
New York
$5.82M -$249K -10,512 -4%
NIP
63
Nicholas Investment Partners
California
$5.76M -$1.33M -56,137 -17%
AAP
64
Ardsley Advisory Partners
Connecticut
$5.68M -$59.2K -2,500 -0.9%
TA
65
Teachers Advisors
New York
$5.66M +$388K +16,398 +6%
Allianz Asset Management
66
Allianz Asset Management
Germany
$4.93M +$5.01M +211,671 +843%
Royal Bank of Canada
67
Royal Bank of Canada
Ontario, Canada
$4.63M -$1.3M -54,940 -20%
California State Teachers Retirement System (CalSTRS)
68
California State Teachers Retirement System (CalSTRS)
California
$4.53M +$372K +15,712 +8%
Creative Planning
69
Creative Planning
Kansas
$4.52M +$19.5K +822 +0.4%
California Public Employees Retirement System
70
California Public Employees Retirement System
California
$4.49M +$879K +37,099 +21%
Man Group
71
Man Group
United Kingdom
$4.23M +$1.97M +83,230 +69%
Swiss National Bank
72
Swiss National Bank
Switzerland
$4.23M – – –
Dimensional Fund Advisors
73
Dimensional Fund Advisors
Texas
$4.15M +$2.68M +113,240 +132%
AllianceBernstein
74
AllianceBernstein
Tennessee
$4.05M -$3.55M -150,000 -44%
FAM
75
Fred Alger Management
New York
$4.05M -$151K -6,377 -3%
1 2
3
4 5

IMMU Hedge Fund Activity: Q3 2018 in Review

207 of the 4,375 institutional investors tracked by Wall St. Rank reported a position in Immunomedics Inc (IMMU) for Q3 2018, worth a combined $3.08B — down 11% from $3.48B a quarter earlier.

Buyers outnumbered sellers: 41 funds opened new IMMU positions and 26 closed out — a net gain of 15 holders — while 81 added to existing stakes and 53 trimmed.

The largest buyer was T. Rowe Price Associates, adding an estimated $90.5M. The largest seller was Millennium Management, cutting an estimated $70.8M.

  • 207 institutional investors held Immunomedics Inc (IMMU) as of Q3 2018, up from 192 in Q2 2018.
  • Funds reported $3.08B of Immunomedics Inc stock for Q3 2018, down 11% quarter-over-quarter.
  • 41 funds opened new Immunomedics Inc positions in Q3 2018 and 26 closed out, a net change of +15 holders.
  • The largest Immunomedics Inc buyer in Q3 2018 was T. Rowe Price Associates, an estimated $90.5M added.
  • The largest Immunomedics Inc seller in Q3 2018 was Millennium Management, an estimated $70.8M sold.

Based on aggregated 13F filings for Q3 2018.